Eta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and
Eta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and vitamin B6-responsiveness. Am J Med Genet 1987, 26(4):959?69. 16. Li SC, Stewart PM: Homocystinuria and psychiatric disorder: a case report. Pathology 1999, 31(3):221?24. 17. Baric I: Inherited disorders in the conversion of methionine to homocysteine. J Inherit Metab Dis 2009, 32(4):459?71. 18. Mattson MP, Shea TB: Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003, 26(3):137?46. 19. Roze E, Gervais D, Demeret S, Ogier de Baulny H, Zittoun J, Benoist JF, Said G, Pierrot-Deseilligny C, Bolgert F: Neuropsychiatric disturbances in presumed late-onset cobalamin C disease. Arch Neurol 2003, 60(10):1457?462. 20. Gilbody S, Lewis S, Lightfoot T: Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol 2007, 165(1):1?3. 21. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J: Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 2008, 98(1?):47?4. 22. Frankenburg FR: The role of one-carbon metabolism in schizophrenia and depression. Harv Rev Psychiatry 2007, 15(4):146?60. 23. Friso S, Choi SW: Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab 2005, 6(1):37?6. 24. Sharma RP: Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics. Schizophr Res 2005, 72(2?):79?0. 25. Regland B: PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26509685 Schizophrenia and single-carbon metabolism. Prog Neuro-Psychopharmacol Biol Psychiatry 2005, 29(7):1124?132. 26. O’Donnell C, Stephens T: The significance of homocysteine levels in schizophrenia. Am J Psychiatry 2005, 162(7):1387?388. author reply 1388?389. 27. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M: Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 2006, 11(2):143?49. 28. Haberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, Karall D, Martinelli D, Crespo PS, Santer R, Servais A, Valayannopoulos V, Lindner M, Rubio V, Dionisi-Vici C: Suggested guidelines for the diagnosis and LosmapimodMedChemExpress Losmapimod management of urea cycle disorders. Orphanet J Rare Dis 2012, 7:32. 29. Singh RH: Nutritional management of patients with urea cycle disorders. J Inherit Metab Dis 2007, 30(6):880?87. 30. Smith W, Kishnani PS, Lee B, Singh RH, Rhead WJ, Sniderman King L, Smith M, Summar M: Urea cycle disorders: clinical presentation outside the newborn period. Crit Care Clin 2005, 21(4 Suppl):S9?7. 31. Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW: Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. A cause of postpartum coma. N Engl J Med 1990, 322(23):1652?655. 32. Enns GM, O’Brien WE, Kobayashi K, Shinzawa H, Pellegrino JE: Postpartum “psychosis” in mild argininosuccinate synthetase deficiency. Obstet Gynecol 2005, 105(5 Pt 2):1244?246. 33. Bachmann C: Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr 2003, 162(6):410?16. 34. Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML: Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res 2009, 66(1):96?01. 35. Legras A, Labarthe F, Maillot F, Garrigue MA, Kouatchet A, Ogier de Baulny H.